Why the study?
Does EGCG protect against doxorubicin-induced toxicity in neonatal rat cardiomyocytes?
Does EGCG protect against doxorubicin-induced toxicity in neonatal rat cardiomyocytes?
EGCG demonstrates cardioprotective effects against doxorubicin-induced oxidative stress and apoptosis in a neonatal rat cardiomyocyte model.
Answers are grounded in this paper and cite their sources.
EGCG attenuates doxorubicin toxicity in rat cardiomyocytes; hypothesis-generating and should not yet inform clinical practice.
Cardiac injury is a major complication of the oxidative stress-generating anticancer drug doxorubicin (DOX). The green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) has been reported to play a cardioprotective role in diseases associated with oxidative stress. The objective of this study was to investigate whether EGCG can protect against DOX-induced toxicity in cardiomyocytes. The data showed that EGCG protected the cardiomyocytes from DOX-mediated cardiotoxicity, as evidenced by decreased lactate dehydrogenase (LDH) activity and increased cell viability in a dose-dependent manner. EGCG treatment also decreased malondialdehyde content and increased protein expression and activities of manganese superoxide dismutase (MnSOD), catalase, and glutathione peroxidase. Furthermore, treatment with EGCG decreased reactive oxygen species (ROS) production and apoptosis. This study suggests that EGCG could protect cardiomyocytes from DOX-induced oxidative stress by attenuating ROS production, apoptosis, and increasing activities and protein expression of endogenous antioxidant enzymes.
No takes yet. Share an insight, caveat, or question.
Li et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: